Article thumbnail

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

By Kimberly Redic, Shannon Hough and Erika Price
Publisher: 'Dove Medical Press Ltd.'
Year: 2016
DOI identifier: 10.2147/ott.s87962
OAI identifier:
Provided by: MUCC (Crossref)

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.